ICU and UNCY update ..part deux . ICU ..turns out the recent funding was all institutional. Institutions now hold close to 22% of the outstanding shares vs 5% previously Funding to aggressively complete enrollment of their pivotal trial ..just my WAG ( wild ass guess )
UNCY ..ARDX just released their earnings report . They declared revenue of $25 m for the qt for their sales of Xphozah ..used to lower serum phosphorus in dialysis patient ...DESPITE no Medicare coverage . 90% of dialysis patients are on Medicare ...so 90% of those on dialysis have no reimbursement for Xphozah ...yet they sell $25m of it last Qt .
That tells me dialysis patients hate their current pho binders . UNCY has a pho binder thats awaiting approval and will be 100% reimbursed by Medicare for the first 2 yrs in TDAPA with declining coverage after that . The problem is that a cGMP manufacturing issue has delayed approval ...and that may delay approval to mid 2026 . But once approved ..if the sales of Xphozah is any indication ...50% complain of diarrhea on Xphozah ...UNCY's OLC could be a game changer JMO and WAG Kiwi
Market Data 
Markets 
AI
